Pershing Square Sohn Cancer Prize
The Pershing Square Sohn Cancer Prize funds early-career scientists to pursue bold, high-impact cancer research with the support of Pershing Square Philanthropies.
Funder: Pershing Square Philanthropies
Due Dates: October 26, 2026: Letter of Intent (LOI) deadline
Funding Amounts: $750,000 total ($250,000/year for 3 years; up to 10% indirect costs included)
Summary: Supports early-career scientists in the US to pursue innovative, high-impact cancer research and accelerate progress toward cancer cures.
Key Information: Since 2026, open to all US institutions; only one LOI per PI, and no full proposal stage.
Description
The Pershing Square Sohn Cancer Prize, administered by the Pershing Square Sohn Cancer Research Alliance (PSSCRA), aims to accelerate breakthroughs in cancer by empowering early-career scientists to pursue bold, high-risk, high-reward research projects. The prize is designed to support innovative cancer research at a stage when traditional funding is often unavailable, and to foster collaboration between academic researchers, clinicians, and the business community. Recipients benefit not only from significant funding but also from access to a unique network, partnership opportunities, and industry engagement to help translate discoveries into clinical solutions.
